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ABSTRACT  
GIT irritation is prominent limitation with the use of Non-steroidal anti-inflammatory drugs (NSAID’s). There is rising interest in designing 
formulations which will deliver the drug at the site of action as topical gels, to avoid GIT irritation and other systemic side effects. Liquid Crystal 
phase has emerged as a novel material for the preparation of topical drug delivery system. In present study the attempt is ma de to prepare 
Lornoxicam loaded lyotropic liquid crystalline gel using glycerol monooleate. Glycerol monooleate is biocompatible, bioadhesive, penetration 
enhancer and sustain release agent. It also promotes ceramide extraction and enhancement of lipid fluidity in the stratum corneum region of 
the skin. Five formulation of lornoxicam were prepared and evaluated for parameters like drug content, viscosity, spreadability, Extrudability 
In-vitro drug release along with in vivo study.  In-Vitro and Ex-Vivo drug release kinetics showed that there was 72.85% and 77.98% drug 
release within 48 hrs. Skin irritation test suggested that prepared formulation was safe for human use. In-Vivo evaluation of this formulation 
was done by carrageenan induced rat paw edema anti-inflammatory model. 
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INTRODUCTION: 
NSAIDs are the best choice to be administered through 
Topical drug delivery system in the management of diseases 
like, Osteoarthritis, rheumatoid Arthritis, and similar 
inflammatory disorders.[1]   
Oral administration of NSAID shows side effects like Nausea, 
Vomiting, Heartburn, Gastric Ulceration, Epigastria. These 
drawbacks can be overcome by developing sustained release 
non-steroidal anti-inflammatory topical gel which is able to 
provide constant drug concentration at the site of 
administration. Hence attempt is to formulate a Liquid 
Crystalline gel (LCG) of Lornoxicam. Glycerol monooleate is 
used to formulate the LCG. (2) GMO is a mixture of the 
glycerides of oleic acid and other fatty acids, consisting 
mainly of the monooleate. GMO offer various Advantages 
like [3] Biocompatibility, Bioadhesiveness, Penetration 
Enhancer, Non Toxic, Non Irritant. Pluronic F 127 is used as 
a stabilizer. The prepared gel is having enhanced 
moisturizing ability.  Moisture content of liquid crystalline 
system is retained for a long time. It promoted the ceramide 
extraction and enhancement of lipid fluidity in the stratum 
corneum region of the skin. [4] These gels are appropriate 
candidates for sustained release because the drug diffusion 
is reduced by a factor of 10 to 1000. [5] Clinical evidence 
indicates that topical gel is a safe and effective treatment 
option for use in the management of skin related disease. [6] 
Topical Drug Delivery System : 
Topical drug administration is a localized drug delivery 
system anywhere in the body through ophthalmic, rectal, 
vaginal and skin as topical routes. [7] 
this avoids first pass effect, GIT irritation, with increased 
patient compliance and ease of application [8], [9]. The only 
major disadvantage associated is that it may cause allergic 
reaction to the skin, skin irritation, dermatitits[10]  
MATERIALS & METHODS :  
Materials:  
Drug Lornoxicam was obtained as a gift sample from 
Macleods pharmaceuticals, Andheri, Campul Glyceryl 
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Monooleate (GMO) - 50, EP/NF was issued from Estelle 
chemicals ltd. Ahmednagar. Pluronic F – 127 (PF 127) was 
Sigma Aldrich. The solvents/chemicals used were obtained 
from the store of Pravara Rural college of Pharmacy, Loni. 
including the solvents/chemicals used were Hydrochloric 
acid, Potassium Chloride, Sodium hydroxide, Potassium 
dihydrogen phosphate, Ethanol etc. [11]   
Method : 
The lipid base (GMO) was melted at 37 0C and after complete 
melting of base the drug was added with constant stirring. At 
the same time the distilled water was heated in another 
beaker and surfactant (PF 127) was added to the aqueous 
base with constant stirring on a magnetic stirrer. Upon 
complete dissolution of the aqueous phase was added drop 
by drop to the lipid phase with constant stirring until a gel 
mass is formed.[12],[13]    
Pre-formulation study : [14 ],[15],[16]  
Confirmation of drug was carried out by using FT-Infrared 
Spectrophotometer, Differential Scanning Colorimeter (DSC) 
and Melting Point.  
Preparation of Standard Calibration Curve : 
Calibration curve of Lornoxicam in pH 6.8 buffer, pH 7.4 
buffer and water was determined using UV visible 
spectrophotometer (UV Thermoscientific). 
Characterization of Lornoxicam lyotropic liquid 
crystalline gel : [ 17],[18] 
Appearance:  
All the batches of Lornoxicam loaded liquid crystalline gel 
formulations were observed for appearance, color, and 
consistency.  
pH :  
 2.0 gm. of gel was accurately weighed and dispersed in 20 
ml of distilled water. The pH of dispersion was measured by 
using digital pH meter. This procedure was carried out in 
triplicate.  
Viscosity : [19] 
 A Brookfield digital viscometer, cone and plate type of 
viscometer was used to determine viscosity of the 
formulations. The viscosity was measured 5 rpm after 30 
seconds, by using spindle no.7 
Drug content : [20] 
0.50 gm. Lornoxicam, liquid crystalline gel was weighed 
accurately. It was added in 100 ml volumetric flask 
containing 100 ml of PBS 6.8. Resultant solution was kept for 
sonication for 30 min. for complete solubility of drug, and 
compared with pure absorbance at same wavelength and 
concentration. Thus % Assay was calculated this procedure 
was carried out in Triplicate.  
Spreadability[13], [14] :- 
A ground glass slide was fixed on the, block an excess of gel 
(about 2 gm) under study was placed on this ground slide. 
The gel was then sandwiched between the slide and another 
glass slide and in the dimensions of fixed ground slide and 
provide with the hook. A 1 kg weight was placed on the top 
of the two slides for 5min to expel air and provide a uniform 
film of gel of the gel between the slides. Excess of gel was 
scrapped of from the edges. The top plate was then 
subjected to pull off 80 gms. With the help of string attached 
to the hook and the time (in sec) require by top slide to 
cover a distance of 7.5 cm be noted. A shorter interval 
indicates better spreadability 
Spreadability was then calculated using the following 
formula:  
 
Where,  
S   = Spreadability of the gel  
M = Weight in the pan (tied on the upper slide) 
 L = Length moved by the glass slide  
 T = the time taken to separate the slide completely from 
each other.  
Extrudability [13]:- 
The measurement of extrudability of each formulation was 
in triplicate and the average values are presented.  
The Extrudability was than calculated by using the following 
formula, 
Extrudability = Applied Weight to Extrude Gel from Tube (In gm) / 
Area (In Cm
2
) 
In-vitro drug release: [ 21], [22] 
The in vitro drug release of the Lornoxicam loaded lyotropic 
liquid crystalline gel was performed to investigate the 
amount of drug released from a gel. Dialysis membrane 
(HIMEDEA) was used as diffusion membrane. Membrane 
was soaked in phosphate buffer 6.8 for 2 hour before 
subjecting to diffusion study. The membrane was positioned 
between the two cell halves of a glass chamber. The two 
compartments were held together with a clamp. The 
receiver/receptor compartment contained 25 ml of 
phosphate buffer. In the upper donor compartment 0.5 gm. 
of formulation was spread evenly on the membrane. The 
receptor phase (phosphate buffer) was continuously stirred 
with the help of magnetic stirrer at 300 rpm and maintained 
at 37oC using a circulating water bath. At predetermined 
time intervals (1, 2, 4, 6, 8, 12, 25, 36, and 48h) 3 ml samples 
were collected from the receiver compartment and replace 
with fresh buffer solution. The samples collected from 
receiver compartment were analyzed for drug content using 
UV spectrometric method at 374 nm wavelength.  
Ex-vivo penetration study : [23] 
Male wistar rats (Animal ethical committee) weighing 200-
250 g were used in this study. Rat abdominal skin was used 
as diffusion membrane. Three ml of the sample was 
withdrawn from the receiver compartment at time intervals 
1, 2,3,4,5,6,12, up to 48 hours and the same amount of fresh 
buffer solution was added to maintain the sink condition in 
receiver compartment. The samples were analyzed 
spectrophotometrically at a wavelength of 374 nm. 
Percentage of Lornoxicam sample was determined by 
referring a previously prepared standard curve. This 
experiment was carried out for a period of 48 hours.  
Skin irritation study :  
Male wistar rats (Animal ethical committee) weighing 200-
250 g; were used in this study. The animals were housed in 
propylene cages, with free access to standard laboratory diet 
and water. Animals were acclimatized for at least seven days 
before study then Lornoxicamlyotropic liquid crystalline gel 
was applied onto the dorsal skin of wistar rats area of 1” X 1” 
square. After a 24 hrs. exposure, the gel was removed; the 
animals were returned to the cages.  
S = M × L/T 
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In-vivo study :  
To carry out in vivo anti-inflammatory studies approval was 
obtained from the Animal Ethical Committee, (PRCOP, Loni) 
and their guidelines were followed for the Studies. The 
sustained anti-inflammatory effect of the optimized 
formulation (F5) was evaluated by carrageenan induced in 
rat hind paw edema method. Young male wistar rats 
weighing (200-250 gm) were randomly divided into three 
groups.  
Table No. 1 : Carrageenan induced paw edema test 
S.N. Groups Animal Weight N 
1 Control Male Wistar 
Rat 
200-250 06 
2 L-LLCG Male Wistar 
Rat 
200-250 06 
3 Volini 
(Marketed) 
Male Wistar 
Rat 
200-250 06 
*N = Number of rats 
The animals were kept under standard laboratory 
conditions, at a temperature of 25±1oC. The animals were 
housed in poly propylene cages, with standard laboratory 
diet. Topical dose of the Lornoxicam loaded lyotropic liquid 
gel was calculated based in the weight of the rats according 
to the surface area ratio. The dorsal side of the rat skin was 
shaved 12h before.  
L-LLCG and marketed formulation (Volini) were applied on 
the dorsal region of all animals except in control group half 
an hour before sub plantar injection of carrageenan in 
distilled water.  
Stability study : [20]  
The ICH Guidelines Q1 a (R2) have established that long 
term stability testing should be done at 25oC/60%RH; stress 
testing should be done at 40oC/75% RH for 6 months. If 
significant change occurs at these stress condition, then the 
formulation should be tested at an intermediate change 
condition i.e. 30oC/75%RH. Table No 2 shows different 
temperatures and period of stability testing. 
  
Table No. 2. ICH Guidelines for stability study  
Study Storage condition Time period 
Long term* 
25oC±2oC/60%RH±5%RHor 
30oC±2oC/65%RH±5%RH 
12 month 
Intermediate** 30oC±2oC/65%RH±5%RH 6 month 
Accelerated 40oC±2oC/75%RH±5%RH 6 month 
*It is up to the applicant to decide whether long term stability study are performed at 25oC±2oC/60%RH±5%RH  or 
30oC±2oC/65%RH±5%RH 
**If 30oC±2oC/65%RH±5%RH is a long term condition there is no intermediate condition.  
Final formulation which was taken for stability. The prepared Lornoxicam loaded lyotropic crystalline gel was packed in 
aluminum collapsible tubes (10g) and subjected to stability studies at 30oC±2oC/65%RH±5%RH for a period of 3 months. 
Samples were withdrawn at 15-day time intervals and evaluated for pH and Drug content. 
Stability Protocol :  
Table No. 3: Stability protocol 
Stability Study (Intermediate  condition) 
Storage condition Duration 
30oC±2oC/65%RH±5%RH 3 month 
 
RESULT& DISCUSSION  : 
Identification and Conformation of Lornoxicam : 
Infrared Spectroscopy :  
Infrared spectroscopy of pure Lornoxicam was carried out for the conformation of the drug.  
 
Fig. 1:  FT-IR Spectrum of Lornoxicam 
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The principal peaks corresponds to the structural features of 
Lornoxicam are found due to presence of C-H  stretching of 
primary carbon at 2889.37 cm-1  the peaks at 2850-2950 cm -
1 and 1064.71 cm -1 indicated presence of free OH stretching 
of carboxylic acid. Peak of 1705 cm-1 confirms presence of 
C=O stretching of carboxylic acid. 
Differential scanning Calorimetry (DSC) : 
The thermal properties of drug can be evaluated by means of 
DSC. 
 
 
Fig. 2 : DSC Thermogram of Lornoxicam 
 
The DSC thermogram of Lornoxicam was typical of 
amorphous substance, exhibiting a sharp endothermic peak 
at 227.1oC corresponding to its melting and decomposition 
reported peak temperature was 226-231oC 
Melting point :  
Melting point of Pure drug (Lornoxicam) was determined by 
capillary method. 
 
Table No. 4 : Melting point of drug by capillary method 
Sample Melting point (Practical) Melting point (Theoretical) 
Drug 225-230oC 226 oC 
 
Drug-Excipient  Interaction Study : 
Fourier Transform Infrared (FT-IR) Spectroscopy: 
 
Fig.3: FT-IR spectrum of drug with physical mixture (PF 127). 
 
From the FTIR spectra it is observed that, peak at 1739 cm-1 
confirms presence of C=O stretching and peak at 1204 cm-1 
further conform the ester group, and peak at 3735 cm-1 
confirms free OH group of monooleate. The principal peaks 
correspond to the structure features of Lornoxicam are 
found due to presence of C-H stretching of primary carbon at 
2889.37 cm-1. The peaks at 2850-2950 cm-1 and 1064.71 cm-1 
indicate presence of free OH stretching of carboxylic acid. 
From the FT-IR spectra it is observed that, all the 
characteristic peaks of drugs appear in the spectra of 
physical mixture at the same wave number indicating no 
interaction between drug, lipid and polymer. 
Stanard Calibration Curves : 
 Standard calibration curves of  lornoxicam were studied at 
pH 6.8,7.4, and in water    (Table no. 5) 
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Table No.5: Calibration curve of Lornoxicam in Water, pH 6.8, & pH 7.4: 
Sr. No 
Conc 
(µg/m) 
Abs. (nm) 
  pH 6.8 pH 7.4 Water 
1 0 0 0 0 
2 2 0.081 0.121 0.067 
3 4 0.148 0.258 0.143 
4 6 0.221 0.409 0.198 
5 8 0.309 0.556 0.258 
6 10 0.399 0.668 0.338 
 
 
Fig. 4: Calibration of Lornoxicam in pH 6.8. 
 
Fig. 5: Calibration curve of Lornoxicam in pH 7.4. 
 
Fig. 6: Calibration of Lornoxicam in Water. 
 
Throat et al                                                                                                               Journal of Drug Delivery & Therapeutics. 2019; 9(6):116-125 
ISSN: 2250-1177                                                                                  [121]                                                                                 CODEN (USA): JDDTAO 
5.Charactarization of Lornoxicam Lyotropic Liquid 
Crystalline Gel : 
 Physical Appearance :  
The Lornoxicam loaded lyotropic liquid crystalline gel (L-
LLCG) formulations were observed under dark background. 
The observations for various formulations are reported in 
table no. 10 showed yellow viscous preparation with smooth, 
homogenous and consistent appearance.  
Table No. 6 :  Appearance of L-LLCG formulation batches 
S.N. Formulations Appearance 
1 F1 Transparent, less viscous 
2 F2 Slight phase separation 
3 F3 
Translucent, smooth, 
viscous 
4 F4 
Translucent, smooth, 
viscous 
5 F5 
Translucent, smooth, 
viscous 
 
 pH : 
The pH of formulations was determined using digital pH 
meter and were found to be in the pH values required for 
topical application. 
Table No. 7 : pH values of L-LLCG formulation batches 
S.N. Formulations pH values 
1 F1 6.6 
2 F2 6.8 
3 F3 7.0 
4 F4 6.9 
5 F5 7.2 
 
Viscosity :  
The viscosity for various formulation batches tabulated in 
Table No. 8. 
Table No. 8: Viscosity study of L-LLCG formulation 
batches 
S.N. Formulations Viscosity (cps) 
1 F1 1130 
2 F2 1850 
3 F3 7520 
4 F4 7730 
5 F5 9200 
 
From the result it was observed that viscosity is increased 
with increase in proportion of GMO. 
  
Spreadability & Extrudability:           
Table1 No. 9: Spreadability study & Extrudability study of L-LLCG  
Formulation  batch  Spreadability (gm.cm/sec.) Extrudability (gm./cm2) 
F1 11.96 12.97 
F2 12.69 13.43 
F3 13.78 14.88 
F4 14.11 15.09 
F5 14.79 15.61 
 
Spreadability was measured on the basis of ‘slip’ and ‘drag’ 
characteristics of gel by using ground glass slide and results 
were found in the range of acceptance. (Table No. 9) 
Drug Content : 
Lornoxicam content in each formulation was determined and 
reported in table no. 10 
 
Table No. 10: Drug content of L-LLCG formulation batches. 
S.N. Formulation Drug content  % 
1 F1 65.58  
2 F2 70.21 
3 F3 76.50 
4 F4 83.32 
5 F5 88.78 
The drug content of optimized formulations (F5) was carried out in triplicate and average drug content was found to be 88.78 
%.  
In-vitro drug release : 
The in vitro drug release from Lornoxicam loaded lyotropic liquid crystalline gel was evaluated by in vitro diffusion study using 
Franz diffusion cell, dialysis membrane was used in phosphate buffer pH 6.8  
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Table No. 11 : In Vitro drug release study of formulation batches : 
Time (hr.) F1 F2 F3 F4 F5 
0 0 0 0 0 0 
1 1.097 2. 921 1.291 3.978 7.683 
2 1.892 3.944 2.567 5.1467 8.834 
3 2.635 5.852 3.727 6.616 9.018 
4 3.659 9.179 4.837 7.245 10.824 
5 3.790 9.880 5.958 8.211 11.634 
6 4.770 10.797 6. 50 9.951 14.968 
7 5.470 12.128 7.723 10.447 17.627 
8 6.702 13.922 8.965 11.116 22.557 
9 7.359 15.786 11.414 13.532 27.861 
10 8.970 17.932 14.102 17.485 33.885 
11 10.254 19.182 17.217 27.563 39.282 
12 12.054 21.016 22.163 36.127 49.892 
24 19.243 30.771 36.515 43.129 58.113 
36 24.482 38.149 39.536 49.668 68.792 
48 26.724 45.338 48.850 58.525 72.853 
 
 
Fig. 8: In vitro drug release study from formulation Batches by using Franz diffusion cell. 
Cumulative drug release from batch F1, F2, F3, F4, and F5 in 
48 hours was found to be 26.724, 45.338, 48.850, 58.525, 
72.853 % respectively. Result indicated that, batch F5 
showed high permeation and hence drug release.  
Ex-vivo study : 
The Ex vivo drug release study of optimize (F5) formulation, 
Rat abdominal skin (0.22µ) was used as diffusion 
membrane. Diffusion study was performed for 48hrs
 
Table No. 12: % ex vivo drug release study optimizes batch (F5) formulation. 
Time (Hrs.) % Drug Release 
0 0 
1 7.387 
2 12.642 
3 14.463 
4 16.352 
5 21.672 
6 25.534 
7 31.138 
8 31.166 
9 43.260 
10 47.155 
11 52.354 
12 62.855 
24 70.958 
36 74.689 
48 77.986 
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Fig. 7: Ex-vivo drug release study from optimize batch (F5) Formulation using franz diffusion cell. 
Cumulative drug release from Lornoxicam lyotropic liquid 
crystalline gel in 48 hrs was found to be 77.98. 
Skin irritation study : 
The result of skin irritation study based on visual 
observation, the observation revealed that, L-LLCG (F5) 
formulation was non-sensitizing and safe for use, as there is 
no irritation produced after application of L-LLCG 
formulation to the rat skin. 
In vivo study : 
Carrageenan induced Rat paw edema test :  
The Carrageenan induced paw edema test carried out by 
using digital plethyesmometer as shown in image.
 
 
Fig.8: In-Vivo study of carrageenan induced paw edema 
 
The Anti-inflammatory effect of developed Lornoxicam 
lyotropic crystalline gel formulation (F5) was compared with 
marketed volini gel. (table 13). The result showed that % 
edema inhibition for L-LLG was 32.16 %, 53.71 and 68.83 % 
and for marketed gel was 41.19 %, 59.57 % and 56.10 % 
after 3, 6 and 12 hr respectively. Initially the percent (%) 
inhibition value was low for Lornoxicam loaded lyotropic 
liquid crystalline gel formulation (F5) but after 3 hr. there 
was significant enhancement in the value which indicated 
the sustained release of Lornoxicam from the formulation 
F5(p<0.05).
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Table No. 13: Observation table for carrageenan induced paw edema 
Group Formulation N Mean wt. (g) Time (h) Mean % 
Edema 
% inhibition 
1 Control 6 250 1 28.7 - 
 3 66.9 - 
6 51.2 - 
12 40.1 - 
2 L-LLCG 6 240 1 25.1 8.75 % 
 3 45.4 32.16 % 
6 23.7 53.71 
12 12.5  68.83 % 
3 Marketed gel 6 245 1 28.2 11.78 % 
 3 39.4 41.19 % 
6 20.7 59.57 % 
12 17.6 56.10 % 
N : Number of rats in each group 
 
Fig. 9 : Percent inhibitions of rat paw edema volume 
 
Accelerated stability study : 
The accelerated stability studies were carried for developed 
optimized formulation (F5) was analyzed for pH and drug 
content. Samples were withdrawn at 15 days interval. After 
6 weeks studies, formulation showed slight changes in pH, 
but it were in acceptable limits (±5). no definite change 
observed for drug degradation as show table. 
 
Table No. 14: Stability study of L-LLCG formulation : 
FORMULATION (F5) Weeks PH Drug content (%) 
  
Lornoxicam Loaded Lyotropic Liquid 
Crystalline Gel 
0 6.6 90.15 
3 6.6 89.85 
6 6.7 88.75 
9 6.7 88.68 
 
CONCLUSION : 
From the summary we can be concluded that the lyotropic 
liquid system provides a novel material for the preparation 
of topical drug delivery system for the poorly water soluble 
drug (Lornoxicam). To achieve this aim, we have selected 
glycerol monooleate for the preparation of lyotropic liquid 
crystal because it is biocompatible, bioadhesive penetration 
enhancer and sustained release agent. According to Ex-vivo 
study drug release was found to be 77.98% in 48 hrs. Shows 
sustained release action. It means the formulated lyotropic 
liquid crystal exhibit good penetration into the skin and the 
systemic circulation. Also this formulation was evaluated for 
spreadability and extrudability.  
The anti-inflammatory activity of this gel formulation in rat 
hind paw edema revealed that Lornoxicam was delivered to 
the inflammation site at a sustained rate over a period of 12 
hr. These results suggest the feasibility of the topical gel 
formulation of Lornoxicam loaded lyotropic liquid 
crystalline gel. 
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